The National Medical Products Administration (NMPA) of China approved Heilongjiang Auridanonide Pharmaceutical Co., Ltd.’s bezoar Qinggan capsules as the first second-level protected variety of traditional Chinese medicine. The protection period is seven years from the date of the announcement. Key highlights include: · Announcement Details: Titled “Announcement on Protected Varieties of Traditional Chinese Medicine (No. 31) (No. 97 of 2025)”, released on 09-Oct-2025. · Protected Variety Information: Bezoar Qinggan capsules assigned protection number ZYB2072025029. · Protection Period: Seven years starting from the announcement date. · Authority: Released by the State Food and Drug Administration on 29-Sep-2025. Freyr can help companies understand and navigate protected TCM varieties, manage intellectual property compliance, and plan regulatory strategies for innovative traditional medicine products in China.

Consult Now

Select Mandate HA
NMPA
Select Mandate Function
Country Regulatory Affairs